生物反馈联合药物治疗慢性前列腺炎的疗效观察

目的探讨生物反馈联合药物治疗慢性前列腺炎的疗效。方法将178例慢性前列腺炎患者随机分为观察组(85例)和对照组(93例)。观察组接受生物反馈治疗20次,每次20 min,同时给予常规药物治疗;对照组仅给予常规药物治疗。以美国国立卫生研究院慢性前列腺炎评分(NIH-CPSI)和前列腺液 (EPS)白细胞计数为评价指标。结果观察组NIH-CPSI总分治疗前后分别为(27．75±5．26)和(10．13±4．96) 分,平均降低16．31分,症状程度评分治疗前后分别为(20．78±5．75)和(8．30±4．42)分,平均降低12．51分;对照组NIH-CPSI总分治疗前后分别为(28．55±7．15)和(18．47±6．75)分,平均降低10．12分,症状程度评分治疗前后分别为(19．27±5．75)和(12．55±5.20)分,平均降低7．67分。观察组显效率(69．4％)、有效率(91．8％)分别与对照组显效率(40．9％)、有效率(67．7％)比较,差异均有统计学意义(P<0．01)。结论生物反馈联合药物治疗慢性细菌性前列腺炎及非细菌性前列腺炎(慢性盆腔疼痛综合征)安全、有效,患者的依从性好。

Efficacy of Biofeedback Combined with Drugs in the Treatment of Chronic Prostatitis

Objective To evaluate the efficacy of biofeedback combined with drugs in the treatment of chronic prostatitis. Methods A total of 178 patients who had been diagnosed as chronic prostatitis and classified according to NIH classification system for prostatitis were divided into two groups. The control group (n=93) received the general drugs, while the treatment group (n=85) received the treatment of biofeedback therapy in addition to the general drugs. The efficacy was evaluated by the NIH chronic prostatitis symptom index (NIH-CPSI) and the WBC count in EPS after the treatment. Results The overall NIH-CPSI scores were averagely reduced by 16.31 in treatment group and 10.12 in control group, and the symptom scores were averagely by 12.51 in treatment group and 7.67 in control group, compared with pre-treatment. Significant differences of reduces were found between two groups (P<0.01). The total effective rates were 91.8% in treatment group and 67.7% in control group (P<0.05). Conclusion Biofeedback combined with drugs in the treatment of chronic bacterial prostatitis and ab-acterial prostatitis is effective and safe. The patients have good compliance with the therapy.